CORAIL: Glycochemistry and bioconjugates

Overview

Our group develops multivalent inhibitors that incorporate multiple ligands onto a single scaffold in order to optimize their binding affinity and inhibitory efficacy. Our main targets are virulence factors, particularly lectins and enzymes, expressed by bacteria of the gut microbiota. In parallel, we are developing new bioconjugation strategies aimed at modifying the surfaces of viral and cellular vectors for applications in gene therapy and cancer immunotherapy. Our innovative and chemoselective approaches enable the specific targeting of selected amino acids on surface proteins, thereby optimizing the functionalization of biomolecules.

Research

Team

Financials

logo ouest valorisation